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Background/Aims: The purpose of this study was to evaluate the value of initial C‑reactive protein (CRP) as a predictor of 
clinical outcome and to investigate whether follow‑up CRP measurement is useful for the prediction of the clinical outcome 
of bloodstream infections in patients with liver cirrhosis (LC), whose CRP production in response to infection may be 
attenuated.
Methods: A retrospective, observational study including 202 LC patients with Escherichia coli or Klebsiella pneumoniae 
bacteremia was conducted to assess the usefulness of serial CRP measurements in predicting clinical outcome in LC 
patients. The CRP ratio was defined as the ratio of the follow-up CRP level to the initial CRP level.
Results: The overall 30‑day mortality rate of the study population was 23.8% (48/202). In the multivariate analysis, 
advanced age (≥ 70 years), healthcare-associated or nosocomial infections, model for end-stage liver disease (MELD) 
score of ≥ 30, and initial body temperature of < 37°C were significant factors associated with mortality (all p < 0.05). No 
association between initial CRP level and mortality was found. In a further analysis including 87 evaluable cases who 
had repeated CRP measurements at day 4 and/or 5, a CRP ratio of ≥ 0.7 was found to be a significant factor associated 
with mortality (odds ratio, 19.12; 95% confidence interval, 1.32 to 276.86; p = 0.043) after adjusting for other confounding 
variables. 
Conclusions: Initial CRP level did not predict mortality of sepsis in LC patients. However, serial CRP measurements 
during the first week of antimicrobial therapy may be useful as a prognostic factor for mortality in LC patients. (Korean J 
Intern Med 2011;26:195-200)
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INTRODUCTION
C-reactive protein (CRP) is an acute-phase protein 
synthesized primarily by the liver in response to tissue 
damage; the only determinant of the serum level is 
the rate of CRP production in the liver [1]. Because 
some biochemical markers of sepsis, such as CRP and 
procalcitonin, closely reflect the activity of infection, 
higher values or a less rapid decline in inflammatory 
variables could be expected in complex cases during the 
treatment of sepsis. CRP is one of the most frequently 
used clinical inflammatory markers that can be obtained 
routinely in every laboratory, making CRP useful in 
diagnosing infection and evaluating a patient’s response to 
antimicrobial therapy.
Production of CRP in response to infection may be 
attenuated in patients with liver dysfunction; this may 
result in difficulties interpreting CRP levels in liver 
cirrhosis (LC) patients [2-4]. Additionally, the value 
of changes in CRP levels over time has not yet been 
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systemically investigated in patients with liver dysfunction. 
Several previous studies demonstrated that decreases 
in CRP levels precede clinical improvement, whereas 
the failure of CRP levels to fall suggests a poor outcome 
in bloodstream infection [5,6], community-acquired 
pneumonia [7,8], ventilator-associated pneumonia [9], 
and infective endocarditis [10]. However, few data are 
available regarding the usefulness of CRP measurement 
for evaluating clinical outcome in LC patients with 
bacteremia. The purpose of this study was to evaluate the 
value of initial CRP as a predictor of clinical outcome and 
to investigate whether follow-up CRP measurement is 
useful for predicting the clinical outcome of bloodstream 
infections in patients with LC.
METHODS
A retrospective, observational cohort study was 
conducted to evaluate the outcomes of cirrhotic patients 
with bacteremia and to assess the usefulness of serial 
CRP measurement for the prediction of clinical outcomes 
in patients with LC. The database at our Clinical 
Microbiology Laboratory and electronic medical records 
were reviewed to identify LC patients with Escherichia 
coli or Klebsiella pneumoniae bacteremia at the Samsung 
Medical Center (Seoul, Korea), a 1,950-bed tertiary care 
university hospital, from January 2003 to December 2007. 
Only patients aged ≥ 18 years with LC were included. 
Among the cirrhotic patients with bacteremia, only those 
who had initial and follow-up CRP levels recorded in their 
medical histories were included. The initial CRP level was 
defined as the level of CRP in the blood samples within 
24 hours after blood culture samples were obtained. The 
day when the blood culture samples were obtained was 
designated as day 0. The follow-up CRP level was defined 
as the level of CRP in the blood samples at day 4 or 5; when 
both values were available, the lower level was adopted 
as the follow-up CRP level. To assess and apply the serial 
change in CRP level in the outcome analysis, we used the 
ratio of the follow-up CRP level to the initial CRP level (CRP 
ratio).
Bacteremia was classified as community-acquired, 
healthcare-associated, or nosocomial using previously 
described criteria [11]. The following variables were also 
recorded and included in the outcome analysis to control 
for potential confounding factors: age, gender, etiology 
of LC, type of bacteremia, infectious focus of bacteremia, 
Child-Turcotte-Pugh score [12], initial body temperature, 
initial white blood cell (WBC) count, sepsis-related organ 
failure assessment (SOFA) score [13], model for end-stage 
liver disease (MELD) score [14], Pitt bacteremia score 
[15], and adequacy of initial antibiotic treatment [16]. The 
primary outcome measure used was 30-day mortality. 
Because this study was observational, patient management 
and antimicrobial treatment regimens were chosen by the 
patients’ physicians with no guidance or intervention from 
the study protocol or study investigators.
The Mann-Whitney U test was used to compare the 
Table 1. Demographic and clinical characteristics of the 
study population
Characteristic  Value (n = 202)
Age, median yr (range)     58 (28‑81)
Gender
Male 138 (68.3)
Female  64 (31.7)
Cause of liver cirrhosis
Hepatitis B virus 134 (66.3)
Hepatitis C virus  26 (12.9)
Alcoholism 20 (9.9)
Cryptogenic 10 (5.0)
Others 12 (5.9)
Acquisition site of bacteremia
Community‑acquired   88 (43.6)
Healthcare‑associated   72 (35.6)
Nosocomial   42 (20.8)
Primary site of infection
Spontaneous bacterial peritonitis   82 (40.6)
Urinary tract infection   39 (19.3)
Unknown   27 (13.4)
Pancreaticobiliary tract infection 16 (7.9)
Liver abscess 13 (6.4)
Varix bleeding   9 (4.5)
Others 16 (7.9)
ESBL‑producing organism
No 187 (92.6)
Yes 15 (7.4)
Child-Pugh classification
Child A 16 (7.9)
Child B  56 (27.7) 
Child C 130 (64.4)
Values are presented as number (%) unless otherwise indicated.
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median values, and the c
2 or Fisher’s exact test was used 
to compare categorical variables. Multivariate logistic 
regression analysis was performed to investigate whether 
initial CRP levels and the CRP ratio were associated 
with the 30-day mortality. To simplify the application of 
the rule, continuous variables were re-categorized into 
binary factors using the most discriminant cutoff point. 
All reported p values were 2-tailed, and p values < 0.05 
were considered to indicate statistical significance. Data 
analysis was performed using commercially available 
software (PASW statistics version 17.0; SPSS Inc., Chicago, 
IL, USA).
RESULTS
In total, 202 cirrhotic patients with E. coli or K. pneumoniae 
bacteremia, whose initial CRP levels were available, were 
included. Demographic and clinical features of the study 
population are shown in Table 1. The most frequent cause 
of cirrhosis was hepatitis B virus (134 patients, 66.3%), and 
the most common focus of bacteremia was spontaneous 
bacterial peritonitis (82 patients, 40.6%). Of the 202 
patients, 130 (64.4%) were classified as Child C according 
to the Child-Pugh classification.
The overall 30-day mortality rate was 23.8% (48/154). 
Factors associated with mortality were advanced age 
(≥ 70 years), healthcare-associated or nosocomial 
infections, Child class C, higher SOFA score, higher 
MELD score, higher Pitt bacteremia score, inappropriate 
initial antimicrobial therapy, lower WBC count, and 
lower body temperature (all p < 0.05) (Table 2). Among 
these variables, age ≥ 70 years (odds ratio [OR], 3.68; 
95% confidence interval [CI], 1.04 to 13.02), healthcare-
associated or nosocomial infections (OR, 4.18; 95% CI, 1.51 
to 11.55), MELD score of ≥ 30 (OR, 7.48; 95% CI, 2.88 to 
19.41), and initial body temperature of < 37°C (OR, 13.85; 
95% CI, 3.81 to 50.34) were found to be significant factors 
associated with mortality in the multivariate analysis (all 
p < 0.05). No association was found between initial CRP 
level and mortality.
A further analysis including 87 evaluable cases who 
had repeated CRP measurements at day 4 and/or 5 was 
performed. Nine of these 87 patients (10.3%) died within 
Table 2. Factors associated with 30-day mortality in cirrhotic patients with Escherichia coli or Klebsiella pneumoniae 
bacteremia
Survivors
(n = 154)
Non-survivors
(n = 48)
p value
Advanced age (≥ 70 yr) 15 (9.7)      9 (18.8)    0.092
Male  102 (66.2) 36 (75)  0.26
Acquisition site of bacteremia    0.011
  Community‑acquired   75 (48.7)   13 (27.1)
  Healthcare‑associated   53 (34.4)    19 (39.6)
  Nosocomial   26 (16.9)    16 (33.3)
ESBL‑producing organism 10 (6.5)      5 (10.4)    0.356
Child-Pugh classification < 0.001
  Child A or B   70 (45.5)    2 (4.2)
  Child C   84 (54.5)    46 (95.8)
SOFA score     5 (0-17)      8 (4‑13) < 0.001
MELD score   18 (1‑40)      31 (17-48) < 0.001
Pitt bacteremia score    1 (0‑5) 1.50 (0‑9)    0.009
Inadequate initial antibiotics 11 (7.1)        9 (18.75)    0.027
Initial CRP, mg/dL 3.785 (0.09-27.77) 3.425 (0.61‑19.82)    0.721
WBC, /mm
3    8,835 (1,100‑31,650)   7,400 (620‑69,290)    0.016
Body temperature, °C 38.6 (35.0‑41.0)  37.9 (35.0‑40.0) < 0.001
Values are presented as number (%) or median (range).
ESBL, extended‑spectrum beta‑lactamase; SOFA, sepsis‑related organ failure assessment score; MELD, model for end‑stage liver 
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30 days. The CRP level decreased below 70% of the initial 
level in only one of the nine non-survivors, whereas 43 of 
the 78 survivors showed decreased CRP levels below 70% 
of the initial level at day 4 or 5 (11% vs. 55%; p = 0.015). 
Factors associated with mortality were advanced age 
(≥ 70 years), extended-spectrum beta-lactamase (ESBL)-
producing organisms, higher SOFA score, higher MELD 
score, and CRP ratio of ≥ 0.7 (all p < 0.05) (Table 3). After 
adjustment for confounding variables, a CRP ratio of 
≥ 0.7 was found to be a significant factor associated with 
mortality (OR, 19.12; 95% CI, 1.32 to 276.86; p = 0.043), 
along with age ≥ 70 years (OR, 39.31; 95% CI, 2.57 to 
369.99; p = 0.007) and higher MELD score (OR, 1.20 [per 
1-point increment]; 95% CI, 1.01 to 1.45; p = 0.043).
DISCUSSION
In the current study, we evaluated the usefulness of 
serial measurements of CRP levels after the initiation of 
antimicrobial therapy in cirrhotic patients with bacteremia 
who might have an attenuated CRP response to infection. 
Our data, which included patients with LC, showed that a 
decrease in CRP level after the initiation of antimicrobial 
therapy was significantly associated with a better outcome, 
although no association between initial CRP level and 
outcome was found. As previously reported by Povoa et 
al. [5] a decrease in CRP level, indicating resolution of 
the inflammatory process, is associated with a better 
outcome, whereas persistently elevated or increasing 
CRP levels, possibly denoting ongoing inflammation, 
are associated with further deterioration and a poor 
prognosis. Persistently elevated or increasing CRP levels, 
even in patients with severe liver dysfunction due to LC, 
can predict a poor outcome. Park et al. [2] demonstrated 
that CRP levels were increased even in LC patients with 
underlying liver dysfunction, despite the fact that the more 
severe the underlying liver dysfunction, the lower the CRP 
response to E. coli bacteremia. Based on the findings in 
these studies, serial CRP level measurements could be 
Table 3. Factors associated with 30-day mortality in cirrhotic patients with bacteremia who had repeated CRP mea-
surements at day 4 and/or 5
Survivors (n = 78) Non-survivors (n = 9) p value
Advanced age (≥ 70 yr)   9 (11.5) 4 (44.4) 0.026
Male  51 (65.4) 8 (88.9) 0.261
Acquisition site of bacteremia
Community‑acquired  37 (47.4) 2 (22.2) 0.178
Healthcare‑associated 31 (39.7) 3 (33.3)
Nosocomial 10 (12.8) 4 (44.4)
ESBL‑producing organism 6 (7.7) 3 (33.3) 0.048
Child-Pugh classification 0.170
Child A or B 38 (48.7) 2 (22.2)
Child C 40 (51.3) 7 (77.8)
SOFA score   5 (0-17) 8 (4‑13) 0.018
MELD score  18 (1‑40) 29 (17-45) 0.004
Pitt bacteremia score  1 (0‑5)                          1 (0‑2) 0.863
Inadequate initial antibiotics   9 (11.5) 2 (22.2) 0.318
Initial CRP, mg/dL        5.64 (0.09-27.77)      2.59 (0.61‑14.26) 0.691
CRP ratio
a of ≥ 0.7 35 (44.9) 8 (88.9) 0.015
WBC, /mm
3          9,000 (1,100‑21,240)           7,820 (1,800‑28,540) 0.435
Body temperature, °C      38.6 (35.5‑41.0)   38.3 (35‑39.2) 0.233
Values are presented as number (%) or median (range).
CRP, C‑reactive protein; ESBL, extended‑spectrum beta‑lactamase; SOFA, sepsis‑related organ failure assessment score; MELD, model 
for end‑stage liver disease; WBC, white blood cell.
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useful as a marker of the resolution of sepsis and might 
help clinicians to make better decisions when reassessing 
patients who fail to improve, including LC patients with 
liver dysfunction.
Serial CRP measurements in patients with sepsis may 
be useful in the identification of patients with the highest 
risk for poor outcome. Earlier prediction of a poor outcome 
could result in prompt and more appropriate management 
of these patients. Similarly, the identification of patients 
in whom a favorable course of disease is expected might 
facilitate therapeutic management of these patients, which 
might include oral antibiotics, instead of intravenous 
antibiotics, or a shorter duration of therapy [10]. However, 
because predictive rules for prognosis serve only as a 
guide to clinical management, CRP levels cannot be used 
as a sole prognostic marker, and should instead be applied 
in combination with other clinical variables that may be 
associated with outcome. Not surprisingly, advanced age 
and severity of the underlying illness (MELD score) were 
also significant factors associated with mortality.
The CRP level was found to be an independent marker 
of severity in community-acquired pneumonia, and an 
elevated CRP, of ≥ 10 mg/dL, was not only associated 
with an increased 30-day mortality, but was also a 
marker for the development of complicated pneumonia 
in a previous study [7]. However, no association between 
the initial CRP level and the 30-day mortality was found 
in our study, including in LC patients with bacteremia, 
although monitoring of CRP levels after the initiation 
of antimicrobial therapy was useful for predicting the 
clinical outcome of the bacteremia. Instead, normal 
body temperature (< 37°C) was a significant factor 
associated with mortality in LC patients with bacteremia. 
Patients with severe liver dysfunction are likely to have 
a blunted inflammatory response. Consequently, these 
patients might have an attenuated CRP response and a 
febrile response to severe infection. This highlights the 
importance of host factors in determining the outcome of 
infection.
Our study has several limitations. First, this was a 
single-center, retrospective observational study, and 
our results have not been validated with a new data set. 
The criteria for performance of blood cultures were not 
standardized, and there was no specific guideline for 
the monitoring of CRP levels. Furthermore, because 
this study was retrospective in nature, the possibility 
that these limitations precluded accurate comparisons 
should be considered. Second, we used all-cause 30-
day mortality, rather than infection-related mortality, 
as an outcome measure. We had difficulty determining 
whether these deaths were directly related to bacteremia 
because the majority of the patients also had underlying 
conditions that could shorten their life spans. Third, our 
study was performed at a single large institution, and the 
results may or may not be applicable to other hospital 
settings. Finally, due to the small sample size (78 vs. 
9 cases) for comparison, the association between the 
CRP ratio and 30-day mortality might not be considered 
justified. Despite these shortcomings, we believe that CRP 
measurement may be useful for monitoring treatment 
response in LC patients with serious bacterial infections. 
To our knowledge, this is the first reported study to 
evaluate the usefulness of CRP level monitoring to predict 
the clinical course of LC patients with bacteremia who 
have liver dysfunction and reduced capacity of CRP 
production.
In conclusion, in LC patients with E. coli or K. pneumoniae 
bacteremia, initial CRP level did not predict prognosis; 
however, when patients survived over 4-5 days of 
antimicrobial therapy, a decrease in CRP level was 
associated with 30-day survival, whereas persistently 
elevated or increasing CRP levels were associated with 
further deterioration and a poor prognosis. Our data 
suggest that serial CRP measurements during the 
first week of antimicrobial therapy may be useful as a 
prognostic factor for mortality in patients with LC despite 
the blunted inflammatory response in such patients.
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